CAMBRIDGE, Mass. & BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s CliniMACS CD34 Reagent ...
Miltenyi Biotec announced today that the FDA had approved its device for humanitarian use in patients with acute myeloid leukemia (AML) who are getting allogeneic stem cell transplants from matched, ...
This seminar will give attendees a full overview of two new Miltenyi cell sorting platforms, the MultiMACS X and the CliniMACS Prodigy and how these instruments can be used in various primary cell ...
Miltenyi Biotec opens first office and Technology Center in Hyderabad, India, focusing on Cell and Gene Therapy (CGT). The Center offers training, research, and manufacturing solutions for CGT, using ...
IsoPlexis, which recently received an NCI grant, reports that it has published a technology note with Miltenyi Biotec in a co-marketing agreement. The tech note (“Getting the most out of your CAR-T ...
Some of the most cutting-edge approaches to treating cancer over the past decade arose from personalized immunotherapy. Chimeric antigen receptor (CAR) T cells can be engineered to specifically target ...
Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft- ...
CliniMACS(R) CD34 Reagent System approved as a Humanitarian Use Device authorized by U.S. Federal law Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results